TECH — Bio-Techne Corporation

Bio-Techne Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $311.4 million, down 2% year-over-year (both organic and reported).
• Adjusted EPS: $0.53, a decrease of $0.03 from the prior year; GAAP EPS rose to $0.32 from $0.14.
• Adjusted Operating Margin: 34.2%, down 70 basis points year-over-year.
• Adjusted Gross Margin: 70.4%, down from 71.6% year-over-year but up sequentially.
• Operating Cash Flow: $86.7 million, with $9.1 million in net capital expenditures.
• Bank Debt: $200 million, down $60 million sequentially.

2. Strategic Updates and Business Highlights

• Market Performance: Strong demand from large pharmaceutical customers, with sustained double-digit growth for six consecutive quarters. U.S. academic market showed stabilization with low single-digit growth.
• Emerging Markets: China achieved positive organic growth for the fourth consecutive quarter, driven by increasing demand from biopharma and CRO customers.
• Product Portfolio:
  • Spatial Biology portfolio grew mid-teens, with a record backlog for the COMET platform.
  • GMP protein portfolio grew nearly 50% year-over-year, excluding impacts from two fast-track cell therapy customers.
  • Proteomic Analysis franchise saw mid-single-digit growth, driven by favorable instrument placements.
• Strategic Brand Alignment: Streamlined portfolio from 10 brands to 3, enhancing customer engagement across research and clinical applications.

3. Forward Guidance and Outlook

• Q4 2026 Expectations: Organic growth expected to be flat, with low single-digit underlying growth excluding GMP headwinds. Anticipated growth in the biotech sector may not materialize until fiscal 2027.
• Fiscal 2027 Outlook: Encouraged by improving funding visibility in biotech, stabilization in academia, and strong pharma demand. Management expects mid-single-digit growth for fiscal 2027, contingent on the recovery of the biotech market.

4. Bad News, Challenges, or Points of Concern

• Emerging Biotech Spending: Continued softness in emerging biotech spending resulted in a 2% organic revenue decline. High single-digit declines were noted in emerging biotech revenues.
• Order Timing Issues: Order timing related to two cell therapy customers created a 400 basis point headwind, impacting revenue.
• Market Dynamics: The funding mix has shifted, with a decrease in early-stage biotech funding affecting core reagent sales.
• Profitability Pressures: Adjusted operating margin declined due to unfavorable product mix and volume deleverage.

5. Notable Q&A Insights

• Biotech Market Trends: Management acknowledged a surprising step down in biotech performance, attributing it to a lag in spending despite improved funding conditions.
• Customer Engagement: Increased interactions with biotech customers were noted, but management remains cautious about assuming immediate recovery.
• China Market Confidence: Management expressed optimism about continued growth in China, citing strong connections with local customers and government officials.
• Competitive Landscape: Management believes their core portfolio remains competitive despite challenges, with confidence in maintaining market share.

Overall, while Bio-Techne faces challenges in emerging biotech spending and order timing, it remains optimistic about its strategic initiatives and the potential for recovery in fiscal 2027.